J&J also committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority (BARDA) to co-fund vaccine research, expanding a previous collaboration. A patient was dosed with Moderna Inc's vaccine in an early-stage trial earlier this month, making it the front-runner in the race to develop a viable vaccine. J&J said in January it had begun working on a possible vaccine for the coronavirus, using the same technologies used to make its experimental Ebola vaccine....
The use of video conferencing services like Zoom and Skype has seen a boom as of late as more look for easier ways to work and communicate remotely. Linguistics tech company Jeenie is looking to offer that same solution for those needing interpretation services....
(Bloomberg) -- The coronavirus threat has handed EasyJet Plc’s founder, top shareholder and biggest critic a new weapon in his longstanding campaign to put the brakes on growth at the discount airline.Stelios Haji-Ioannou, who quit the board in protest over its expansion in 2010, has renewed his demand the U.K. carrier cancel an order for more than 100 Airbus SE narrow-body aircraft, arguing that the 4.5 billion-pound ($5.6 billion) cost threatens to drag the company down as the coronavirus pandemic cripples industry growth.The entrepreneur, who controls 34% of the stock, threatened to call one shareholder meeting a week to remove directors if he doesn’t get his way.“Even with a resumption of air traffic, any income from passengers is likely to be too low to keep up with outgoings and would most likely render EasyJet insolvent if it continues to pay Airbus for more aircraft,” Haji-Ioannou said in a letter to the...
Generic drugmaker Mylan NV has offered concessions to address European Union antitrust concerns about its bid for Pfizer's off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday. U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines. The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27....
